Research
Correction: Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1
(Corrects rating change in headline.)(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ANTX
